Perioperative Application of Omega-3 Polyunsaturated Fatty Acids in Gastric Cancer Patients

NCT01910948 | Unknown Phase 4

• 1 other identifier: omega-3 PUFA
• Study Type: interventional
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

To evaluate immunomodulatory effects of perioperative application of omega-3 polyunsaturated fatty acids in gastric cancer surgery, the effects of postoperative recovery, the improvement of nutritional status, incidence rate of related complications, and whether it can reduce the average postoperative hospitalization days.

Conditions

Gastric Cancer

Keywords

omega-3 gastric cancer perioperation

Outcome Measures

Primary Outcomes (1)

• blood immune factors

  10 days

Study Arms (1)

omega-3 polyunsaturated fatty acids

EXPERIMENTAL

The included patients will be randomly divided into two groups A and B, two groups of patients 4 days before operation begin to give parenteral nutrition: A: the control group of normal intravenous nutrition. B: the trial group,add omega-3 polyunsaturated fatty acids 0.2 g/kg to parenteral nutrition, no use on the day of surgery, postoperative 2 days continue to add omega-3 polyunsaturated fatty acids 0.2 g/kg.

Drug: omega-3 polyunsaturated fatty acids

Interventions

omega-3 polyunsaturated fatty acids DRUG

The included patients will be randomly divided into two groups A and B, two groups of patients 4 days before operation begin to give parenteral nutrition: A: the control group of normal intravenous nutrition. B: the trial group,add omega-3 polyunsaturated fatty acids 0.2 g/kg to parenteral nutrition, no use on the day of surgery, postoperative 2 days continue to add omega-3 polyunsaturated fatty acids 0.2 g/kg.

Also known as: omega-3 PUFA, ω-3 PUFA

omega-3 polyunsaturated fatty acids

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients coming to FirstJilinU diagnosed gastric cancer by endoscopy and pathology.
• No preoperative treatment, the gastric cancer radical surgery in our hospital is the first treatment.
• Nutrition screening score (NRS 3 or higher).
• Albumin and (or) immune enhancer were not used within two weeks before operation .
• No blood system diseases.

You may not qualify if:

• Being in the acute phase of inflammation before operation and emergency surgery.
• Patients combined metabolic diseases such as diabetes, hyperthyroidism, immune system disease or taking immunosuppressants;
• Combined hepatic insufficiency.
• Spleen resected in operation

Sponsors & Collaborators

• Jian Suo: lead

MeSH Terms

Conditions

Stomach Neoplasms

Interventions

Docosahexaenoic Acids

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases

Intervention Hierarchy (Ancestors)

Fatty Acids, Omega-3; Dietary Fats, Unsaturated; Dietary Fats; Fats; Lipids; Fatty Acids, Unsaturated; Fatty Acids; Fish Oils; Oils

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Headmaster, Dept.of General Surgery

Study Record Dates

• First Submitted: July 23, 2013
• First Posted: July 30, 2013
• Study Start: June 1, 2013
• Primary Completion: December 1, 2013
• Study Completion: March 1, 2014
• Last Updated: July 30, 2013

Record last verified: 2013-07